Illinois Biotechnology Industry Organization Makes Notable Additions to Board of Directors

CHICAGO--(BUSINESS WIRE)--The Illinois Biotechnology Industry Organization (iBIO) today announced the election of new additions to its Board of Directors. About Motrin (Ibuprofen) The new Board members, who include senior executives and specialists from highly-recognized organizations, add depth and prestige to an already-strong lineup of medical, agricultural, and industrial biotech representation. Joining iBIO’s Board are Walt Johnston and David Flowers. Walt Johnston is Vice President, US Marketing and Strategic New Product Planning for Astellas Pharma US, Inc., a global research-based pharmaceutical company committed to serving unmet medical needs in Oncology, Cardiology, Immunology, Infectious Diseases, Urology and Neuroscience. Walt has over 20 years of experience in the pharmaceutical industry. Lamprene (Clofazimine) without prescription He leads marketing activities and programs across several therapeutic areas of the Astellas US business to ensure superior commercial performance, with primary responsibility for Urology, Immunology, Cardiovascular and Anti-Infective markets. Gestanin (Progestogen) with free Rx Walt also serves as a member of the Astellas Portfolio Strategic Executive Committee. “I am excited to join iBIO’s board during a period of unprecedented innovation and opportunity across the life sciences,” said Johnston. Buy Divalproex with free prescription “I am looking forward to working with iBIO’s board members and staff to contribute to the future progress of the organization and the industry.” “iBIO is fortunate to have members of Walt Johnston and David Flowers caliber join our board,” said Warren Ribley, iBIO President & CEO, “The leadership and experience that Walt and David bring to our board will be a great benefit to our organization and community.” David Flowers is a Director, Life Sciences Industry, for Deloitte Services LP. Buy Tetracycline (Tetracycline Hydrochloride) with no prescription The subsidiaries of Deloitte LLP provide industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including 80 percent of the Fortune 500. Flowers has more than 26 years of experience serving multi-national and global companies, including 16 years dedicated to the Life Sciences sector. Buy Vitamin C online Additionally, he is on the leadership team contributing to the development of Deloitte’s long-range global and Chicago marketplace strategies for the Life Science sector. “Deloitte and iBIO have a strong collaborative history,” said Flowers. http://cardiobloodreview.wordpress.com “Joining iBIO’s board provides me with the opportunity to continue to expand Deloitte’s contribution to the Illinois life sciences community.” About the Illinois Biotechnology Industry Organization iBIO’s mission is to make Illinois and the surrounding Midwest one of the world’s top life sciences centers: a great place to do business and a great place to grow technology ventures. iBIO, working on its own and through valued partners Promotes sound public policy at the local, state and federal levels; Improves our region’s ability to create, attract and retain businesses Orchestrates industry involvement to help solve America’s math and science education crisis Builds community by providing opportunities to connect and engage with the industry We thereby contribute to the well-being of people worldwide while creating new jobs, attracting firms to the region and generating prosperity. iBIO’s Leadership Sponsors are AbbVie, Astellas US, Baxalta, Horizon Pharma and Takeda Pharmaceuticals North America.

Exelixis Appoints Chris Senner as Executive Vice President and Chief Financial Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. Isordil Sublingual (Isosorbide Dinitrate) without prescription (NASDAQ:EXEL) today announced the appointment of Christopher J. About Niaspan (Niacin) with no prescription Senner as Executive Vice President and Chief Financial Officer. Buy Vigora (Sildenafil Citrate) without Rx Mr. Buy Dexamethasone Senner has nearly 25 years of experience in biopharmaceutical finance, including deep expertise in global financial operations and controls, strategic planning and analysis, supply chain finance and business development. Buy Vigora (Sildenafil Citrate) without Rx He joins Exelixis after five years at Gilead Sciences, where he served as Vice President, Corporate Finance. Buy Stretch Marks online He previously spent eighteen years at Wyeth in a variety of financial roles with increasing responsibility for many of the company’s divisions and regions. http://allegra-opinion.blogspot.com He joins Exelixis in advance of several potentially transformational milestones anticipated this year, including top-line results from the METEOR phase 3 pivotal trial and the potential U.S. and EU regulatory approvals of cobimetinib, a compound discovered by Exelixis and then licensed to Genentech for further development and commercialization. In this role, Mr. Senner will oversee the company’s global finance function, leveraging extensive experience gained earlier in his career. While at Gilead, he was accountable for controllership and operational financial planning and analysis, including research and development, manufacturing, commercial operations, and tax and treasury planning. At Wyeth, he served in a variety of capacities, most notably as CFO of the company’s $10 billion U.S. pharmaceuticals business and the BioPharma Business Unit, a $5 billion global inflammation, oncology and hematology business. “With more than 25 years of service between two of the biopharmaceutical industry’s most highly-regarded companies, Chris Senner is exceptionally well prepared to lead Exelixis’ finance function as our next CFO,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. “Chris’ global commercial finance expertise will serve Exelixis well as we prepare for top-line results from METEOR and the potential regulatory approval of cobimetinib, two milestones that we hope will advance and accelerate the company’s transformation into a global commercial organization.” Mr. Senner will succeed Deborah Burke, who has served as Senior Vice President and Chief Financial Officer since September 2014. Ms. Burke joined Exelixis in 2005 and was the company’s Vice President, Finance and Controller before being appointed interim CFO in June 2014. She will remain with Exelixis in the role of Senior Vice President, Finance and Controller. “I’d like to thank Debbie for her many contributions as Chief Financial Officer over this past year. Her support has been invaluable as we have navigated through a challenging time for the company,” continued Dr. Morrissey. “We are fortunate that we will continue to have the benefit of her input and experience as we move forward.” “It is a very exciting time to join Exelixis,” said Mr. Senner. “Should its near-term catalysts prove positive, the company is poised to make additional, important contributions to the treatment of cancer and dramatically advance its commercial presence. I’m looking forward to working with Mike, Debbie and the rest of the Exelixis team to make the most of the potential opportunities that lie ahead.” About Exelixis Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company s web site at .exelixis.com. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: anticipated developments and timing with respect to Exelixis’ ongoing phase 3 pivotal METEOR trial of cabozantinib in renal cell carcinoma; cobimetinib regulatory filings and future potential approvals; and, Exelixis’ belief that its compounds have the potential to meaningfully improve cancer care. Words such as “potential,” “transformation,” “anticipates,” “will,” “advance,” “hope,” “looking forward,” “believe,” “poised,” or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Exelixis’ actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the expected times; risks related to the potential failure of cabozantinib, cobimetinib and other Exelixis compounds to demonstrate safety and efficacy in clinical testing; the clinical, therapeutic and commercial value of cobimetinib, cabozantinib and other Exelixis compounds; Exelixis’ dependence on its relationship with Genentech/Roche with respect to cobimetinib and Exelixis’ ability to maintain its rights under the collaboration; the uncertainty of regulatory approval processes; the sufficiency of Exelixis’ capital and other resources; the uncertain timing and level of expenses associated with the development of cabozantinib; risks and uncertainties related to Exelixis’ compliance with applicable regulatory requirements, including healthcare fraud and abuse laws and post-marketing requirements; Exelixis’ dependence on third-party vendors; market competition; changes in economic and business conditions; and other factors discussed under the caption “Risk Factors” in Exelixis’ quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on April 30, 2015 and in Exelixis’ other filings with the SEC. The forward-looking statements made in this press release speak only as of the date of this press release. Exelixis expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Bioanalytical Systems, Inc. About Glucovance (Glyburide(Glibenclamide)-Metformin) without Rx (NASDAQ:BASI) has entered into an agreement with PDS Life Sciences (PDS) to fully upgrade its laboratory information management system (LIMS) to Ascentos™. About Pamelor (Nortriptyline) The new Ascentos software represents the next generation of preclinical research LIMS and is a fully integrated software solution that includes toxicology, clinical pathology, toxicokinetics and pathology modules that streamline data management and reporting. BASi will also implement the TranSEND™ solution as part of the enhancements being made by the company. Buy Kamagra Soft (Sildenafil Citrate) The new automated software converts study data to the new Standard for Exchange of Nonclinical Data (SEND) format that will be required by the FDA beginning in December 2016. Buy Dermol with no Rx TranSEND effectively aggregates and translates data from multiple LIMS to produce one set of harmonized and validated SEND files as required by the FDA. Buy Women Pack-40 () with no prescription With this sophisticated tool, BASi will now be able to provide SEND study datasets that are ready for electronic data submission to the FDA without any further processing by the client. BASi President and CEO Jacqueline Lemke said, “Upgrading to PDS’ Ascentos and the addition of the TranSEND solution represent vital enhancements to our IT infrastructure that will harmonize data collection and reduce the time to complete a study and deliver our report.” Philip A. Buy Slippery Elm online Downing, vice president of preclinical services at BASi, concluded, “Being able to provide the data in SEND-ready format will shave weeks to months off of clients’ timelines since there is no need to do the SEND conversion themselves.” “We are very excited to expand our relationship with BASi because the company has always been unique in having both sophisticated lab instrumentation and preclinical research services. http://doctor-answers.blogspot.com/ Since PDS already has extensive experience in SEND dataset conversion, we look forward to helping BASi become one of the leaders in the CRO field regarding electronic submission compliance. This capability will be a real value added service for BASi clients,” said Sayed Badrawi, CEO of PDS Life Sciences. BASi expects final installation of the various modules to be completed this summer with validation testing continuing throughout the rest of the calendar year 2015 and full validation being completed well in advance of the FDA-mandated deadline of December 2016. About Bioanalytical Systems, Inc. BASi™ is a pharmaceutical development company with over 40 years of regulatory excellence in providing contract research services and monitoring instruments to the world s leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit .BASinc.com for more about BASi. About PDS Life Sciences For more than 30 years, PDS has provided intuitive data management software and solutions for life sciences research and development programs worldwide. Most of the world’s top 10 pharma companies rely on PDS software, as do industry-leading CROs, chemical companies, universities and regulatory agencies. The PDS software lineup is centered on Ascentos™, your integrated preclinical software solution, which is purpose-built to support toxicology, clinical pathology, reproductive toxicology and anatomic pathology. PDS also offers TranSEND™, your complete FDA submission management solution, as well as powerful bioinformatics analysis and other services. Learn more at pdslifesciences.com.

Global Motor Neurone Diseases Pipeline Insights Report 2015

. Anafranil (Clomipramine HCI) without Rx DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/ktrcz4/motor_neurone) has announced the addition of the "Motor Neurone Diseases-Pipeline Insights" report to their offering. Motor Neurone Diseases Pipeline Insights provides the in-depth analysis of the pipeline assets across the Motor Neurone Diseases. Buy Protein Blends online Buy Danocrine (Danazol) The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. http://doctoranswers.wordpress.com Serevent Inhaler (Salmeterol) The Motor Neurone Diseases Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. Motor Neurone Diseases Pipeline Insights Report covers the Motor Neurone Diseases pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. About Robaxin (Methocarbamol) The Report also provides Motor Neurone Diseases related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. Cytomid without Rx The Report also highlights the discontinued and inactive projects in pipeline for Motor Neurone Diseases. Scope - The report provides a Motor Neurone Diseases Landscape across the globe - The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information - Coverage of the Motor Neurone Diseases pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Motor Neurone Diseases and also provide company profiling - Pipeline products coverage based on various stages of development from NDA filings to discovery. - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type For more information visit .researchandmarkets.com/research/ktrcz4/motor_neurone

New imaging technique spots early stages of dangerous artery deposits

Atherosclerosis - where fatty calcium deposits clog up arteries and reduce blood flow and oxygen supply - can lead to heart attacks and strokes. Buy Danocrine (Danazol) Now, a team says it is possible to identify the early stages of this process on a noninvasive imaging system thanks to an inexpensive, repurposed radioactive agent. In some cases of atherosclerosis, pieces can break off from the calcium deposits. In Nature Communications, researchers from the universities of Cambridge and Edinburgh in the UK, describe how they used a radioactive agent that was first developed in the 1960s to detect bone cancer to highlight the build-up of unstable calcium deposits in patients arteries. Study leader Dr. Serevent Inhaler (Salmeterol) Anthony Davenport, of the department of medicine at Cambridge, says this "new emerging technique is the only imaging platform that can noninvasively detect the early stages of calcification in unstable atherosclerosis." He and his colleagues expect the technique - which uses sodium fluoride tagged with a tiny amount of radioactive tracer - will help diagnose atherosclerosis and develop new drugs to treat it. There are several ways atherosclerosis can be dangerous. About Robaxin (Methocarbamol) One way is that the gradual build-up of fatty deposits (known as "plaques") gradually harden and narrow the artery wall, eventually restricting blood flow and oxygen supply. Not clear which patients will develop dangerous, unstable calcium deposits Another way that atherosclerosis can be dangerous is that in some cases, pieces can break off from the calcium deposits. Cytomid without Rx If that happens in an artery that supplies the brain or the heart, it can cause a blockage that results in stroke or heart attack. While it is clear that atherosclerosis can lead to very serious disease, what is not so clear is which people will develop the unstable plaques that allows pieces to break off - so the earlier they can be identified, the better the chances that early treatment will save lives. For their study, the team injected patients with the radiotracer version of sodium fluoride (18F-NaF). Then, using a combination of imaging techniques (positron emission tomography and computed tomography, or PET/CT), they tracked the tracer as it moved around the body. "Sodium fluoride is commonly found in toothpaste as it binds to calcium compounds in our teeth s enamel," Dr. Anafranil (Clomipramine HCI) without Rx Davenport explains, "In a similar way, it also binds to unstable areas of calcification in arteries and so we re able to see, by measuring the levels of radioactivity, exactly where the deposits are building up." Sodium fluoride tracer should revolutionize detection of dangerous calcium deposits After undergoing the scans, the patients had surgery to remove the plaques in their arteries. Buy Protein Blends online The researchers then examined them at a higher resolution using a laboratory PET/CT scanner and an electron microscope. This detailed examination confirmed that the 18F-NaF tracer builds up in areas of active, unstable calcium deposits, and not in surrounding tissue. Co-author, Dr. http://doctoranswers.wordpress.com James Rudd, a cardiologist and researcher at Cambridge, says 18F-NaF is a simple and inexpensive tracer that should "revolutionize" the ability of doctors to detect dangerous calcium deposits in the arteries of the heart and brain. He concludes: "This will allow us to use current treatments more effectively, by giving them to those patients at highest risk. In addition, after further work, it may be possible to use this technique to test how well new medicines perform at preventing the development of atherosclerosis." Most of the funds for the study came from the Wellcome Trust, supplemented with contributions from the British Heart Foundation, Cancer Research UK and the Cambridge NIHR Biomedical Research Centre. In February 2015, Medical News Today learned how researchers are working on a way to get nanomedicines to treat atherosclerosis. Writing in Science Translational Medicine, a Harvard-led team describes how they developed nano-sized "drones" that deliver targeted drugs and repair arteries. The tiny particles were small and sticky enough to push their way under the calcified deposits and effect repair. Written by Catharine Paddock PhD

Neutralizing antibodies investigated for HIV vaccine

Two studies published in PLOS Pathogens this month shed further light on the effect of neutralizing antibodies in the steep challenge facing researchers to develop a vaccine against AIDS/HIV. Buy Colcrys (Colchicine) Nabs are immune proteins that can recognize, bind to, and trigger the elimination of a virus. About Stromectol (Ivermectin) Image credit: Dr. About Mentat () with no prescription Alexandra Trkola The search for an effective vaccine for AIDS/HIV has long been a battle for scientists and researchers around the world. Buy Cutizone Although HIV incidence have remained stable around the world at 50,000 new infections per year, a cure still remains to be found. Neutralizing antibodies are immune proteins that can recognize, bind to, and trigger the elimination of a virus before it can establish a chronic infection. Ashwagandha () with free prescription Nabs have previously been researched as a tool against HIV and AIDs. Buy Plant Sterols online In a study last year, scientists discovered for the first time how to create Nabs in those already infected with HIV-1. http://future-pharmaceuticals.blogspot.com Dr. Julia Overbaugh, from the Fred Hutchinson Cancer Research Center in Seattle, WA, and her team, focused on the role of Nabs in those "superinfected" with HIV, which is defined as those sequentially infected at least twice with HIV by different sexual partners. Results from 21 women who were tested suggest that Nabs mount a broad and potent response against diverse HIV subtypes. It is hoped that that this particular response can be mediated at least in part by polyclonal antibodies, which can then target different aspects of the virus. These findings follow on from the team s previous research into the superinfected. In that study, it was discovered that those infected twice had a more potent antibody response to the virus - which inhibited the virus from replicating - compared with women who have only been infected once. Dr. Overbaugh hopes further research can be done on those superinfected, stating further research may "provide insight to the development of a diverse Nab response with multiple epitope specificities." Direct cell to cell transmission more prone to mutation strains The second study published in PLOS Pathogens focused on Nabs effect on those infected with HIV/AIDS by cell-to-cell contact. Dr. Alexandra Trkola from the University of Zurich, Switzerland, and her colleagues, developed an assay that can specifically test the potency of Nabs to prevent direct cell-to-cell transmission of HIV. By establishing an assay system, the free virus infection is restricted, resulting in infections only occurring through cell-to-cell transmissions. Researchers were able to test whether a large selection of Nabs could prevent cell-to-cell transmission of different HIV strains. Although Nabs showed an overall decrease in activity, losses varied substantially depending on the antibody and virus strain examined. Scientists also discovered certain Nabs still retained activity during cell-to-cell transmission for individual viruses. However, this was generally not linked to a high potency of the free virus, but instead, displayed Nabs inhibiting prior to the binding of the virus to the CD4 receptor on T cells. Mathematical analysis showed that when the virus was transmitted via cell to cell transmission, it was substantially more prone to give rise to mutation strains that can escape immune control compared to free virus transmissions. Dr. Trkola said: "This highlights the importance of controlling virus replication via the cell-cell transmission pathway even if the contribution of this transmission should provide to occur to a less extent than free virus spread in infected individuals." Written by Peter Lam

Does cigarette smoking contribute to schizophrenia?

A meta-analysis published in the journal Lancet Psychiatry reports that people who smoke are more than three times more likely to suffer from psychosis, compared with nonsmokers. Researchers previously thought people with psychosis are more likely to smoke because they may find that smoking counteracts side effects from schizophrenia medication. Previous studies have reported a link between smoking cigarettes and psychosis. Atarax (Hydroxyzine) with free Rx However, few studies investigated cigarettes as a direct driver of this association. About Viagra Super Dulox-Force (Sildenafil Citrate + Duloxetine) without Rx Instead, researchers had hypothesized that people with psychosis are more likely to smoke because they may find that smoking counteracts side effects from schizophrenia medication or negative schizophrenia symptoms. One problem with this hypothesis, however, is that rates of smoking would only increase after someone has developed psychosis for this to be the case. The new meta-analysis, conducted by researchers at King s College London in the UK, assessed evidence from 61 observational studies, which involved 15,000 tobacco users and 273,000 nonusers overall. The analysis shows that 57% of people presenting with a first episode of psychosis were smokers - this means they were three times more likely to be smokers than healthy, nonsmoking study participants. Daily smokers were also found to develop psychotic illness around 1 year earlier on average than nonsmokers. These findings shed doubt on the theory that an association between smoking and psychosis exists because people with psychosis use cigarettes to self-medicate, claim the authors. "While it is always hard to determine the direction of causality," says Dr. About Arcoxia (Etoricoxib) without Rx James MacCabe, clinical senior lecturer in Psychosis Studies at the King s Institute of Psychiatry, Psychology & Neuroscience (IoPPN), "our findings indicate that smoking should be taken seriously as a possible risk factor for developing psychosis, and not dismissed simply as a consequence of the illness." Because very few of the studies in the meta-analysis took into account consumption of substances other than tobacco, it was difficult for the King s team to rule out other factors that may contribute to the association between smoking and psychosis. Nicotine, psychosis and dopamine The researchers do, however, propose another hypothesis that could explain the association. About Cobix Sir Robin Murray, professor of Psychiatric Research at the IoPPN, points to the brain s dopamine system: "Excess dopamine is the best biological explanation we have for psychotic illnesses such as schizophrenia. About Chloromycetin (Chloramphenicol) without Rx It is possible that nicotine exposure, by increasing the release of dopamine, causes psychosis to develop." "Longer-term studies are required to investigate the relationship between daily smoking, sporadic smoking, nicotine dependence and the development of psychotic disorders," says IoPPN research fellow Dr. Buy Natural Cosmetics online Sameer Jauhar. "In view of the clear benefits of smoking cessation programs in this population every effort should be made to implement change in smoking habits in this group of patients." A 2014 study conducted by researchers from the Washington University School of Medicine in St. http://doctorconsult.wordpress.com Louis, MO, found that people with severe mental illness such as schizophrenia or bipolar disorder have a higher risk for substance abuse - especially cigarette smoking. In that study, people with severe mental illness were: 4 times more likely to be heavy alcohol users (four or more drinks per day) 3.5 times more likely to use marijuana regularly (21 times per year) 4.6 times more likely to use other drugs at least 10 times in their lives 5.1 times more likely to be daily smokers. Written by David McNamee

Drug combo shows promise against rare bone cancer

Like other cancers, tumor cells in Ewing sarcoma - a rare bone cancer that primarily affects children and young adults - have to keep repairing their faulty DNA to survive. Buy Altace (Ramipril) with free Rx Now, a team of researchers shows two drugs that interfere with this process work together very effectively to kill the cancer cells in lab cultures and mice. The researchers found that the drug combination inhibited cell proliferation and facilitated cell death in lab cultures of Ewing sarcoma cancer cells and mice with tumors. The team - including members from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, Spain - describes the finding in the journal Oncotarget. Ewing sarcoma tumors usually grow in the hip bones, the ribs, or in the middle of long bones, such as the legs or arms. Buy Xylocaine (Lidocaine) It can also grow in the spine and soft tissue around the bone. Most Ewing tumors are diagnosed in teenagers, but they can also affect children and young adults in their 20s and 30s. Actos (Pioglitazone) with free Rx Each year in the US, around 250 children and teenagers are diagnosed with a Ewing tumor - most of which will be Ewing sarcoma of bone. The 5-year survival rate for people with a Ewing tumor that has not spread is about 70%. About Clomid without prescription If the tumor has spread (metastasized) when the disease is diagnosed, the 5-year survival drops to less than half of this. The most common mutation that causes Ewing sarcoma involves two genes - the EWSR1 gene on chromosome 22 and the FLI1 gene on chromosome 11. Buy Cialis Super Active (Tadalafil) with free Rx These changes occur during a person s lifetime and are only present in tumor cells. Buy Minerals online They are not inherited. The new study builds on previous research that suggested some types of Ewing sarcoma could be particularly sensitive to a group of drugs called PARP inhibitors, if used in combination with DNA damage repair agents. Olaparib and Trabectedin combination was highly synergistic Cancer cells - like healthy cells - rely on DNA repair to maintain their genetic integrity in order to multiply and spread. http://webmd-board.blogspot.com There are a number of cellular processes that carry out DNA repair. One such process relies on a family of proteins called PARP. However, many cancers favor PARP as the DNA repair mechanism, which is why PARP inhibitors were developed to treat cancer. One type of PARP inhibitor is a drug called Olaparib - one of the drugs that the study investigates. Olaparib blocks the action of PARP1, a gene that triggers DNA repair when damage is detected. The other drug the study investigates - Trabectedin - is also used as an anti-tumor treatment. It works by causing breaks and abnormal DNA structure in cancer cells, which in turn triggers cell death. The researchers tested the effect of the two drugs together on Ewing sarcoma. They ran two sets of tests - one on cancer cells (in vitro) and the other on mice implanted with grafts of human Ewing sarcoma tumors (in vivo). In their study paper, they note how the "combination of Olaparib and Trabectedin was found to be highly synergistic." It inhibited cell proliferation and facilitated cell death. In the mice, the tumors showed complete regression. Senior author Enrique de Alava, of the Instituto de Biomedicina de Sevilla (IBiS) and the Virgen del Rocio Hospital in Seville, concludes: "Our results demonstrate that the combination of Trabectedin and Olaparib could be a new therapeutic strategy that should be studied in greater depth so that it can benefit patients with this disease in the near future." In February 2014, Medical News Today also learned about an earlier international study led by IDIBELL that suggested a treatment option for metastatic Ewing sarcoma might be found in switching off the gene SIRT1, which codes for the protein Sirtuin1. In that study, the team showed that overexpression of Sirtuin1 was very significantly linked to metastasis in samples from patients with Ewing sarcoma. Written by Catharine Paddock PhD

Emotional awareness training 'reduces severe crime reoffending rates'

. http://webmdhelp.wordpress.com Buy Linseed Oil online Buy Duphaston (Dydrogesterone) with free prescription About Cialis with free prescription Ticlid (Ticlopidine) with free Rx About Arava (Leflunomide) without prescription Viagra Strips (Sildenafil Citrate) with free prescription

Cystic fibrosis gene therapy trial offers hope of treatment

. http://webmd-magazine.blogspot.com he results of a trial provide the first proof of concept that non-viral gene therapy is safe and can benefit lung function in patients with cystic fibrosis, say investigators writing in The Lancet Respiratory Medicine. Trial participants receive the gene therapy by inhaling fat globules containing the corrective DNA. Buy Zyprexa (Olanzapine) with free Rx Image credit: Imperial College London The trial - run by the UK Cystic Fibrosis Gene Therapy Consortium - now needs to be followed by further studies to assess the optimum dose and treatment schedule, they add. The placebo-controlled, double-blind trial was carried out at two centers in the UK and recruited 136 cystic fibrosis patients over the age of 12. The patients received either monthly doses of the gene therapy or a placebo for 1 year. The trial tested a gene therapy where the patient inhales molecules of DNA wrapped in fat globules (liposomes) that deliver a correct copy of the gene into the cells in the lung lining. Cystic fibrosis is a condition where the lungs produce too much thick mucus, making breathing difficult and increasing the risk of infection. The disease is caused by a single faulty gene located on chromosome 7. Gene therapy shows significant but modest benefit After 1 year of treatment, compared with placebo, patients who received the gene therapy showed "a significant, albeit modest, benefit" in forced expiratory volume or FEV in 1 second (a measure of lung function), write the study investigators, who note that such a result indicates a "stabilization of lung function in the treatment group." They conclude the trial is the first to show that repeated doses of gene therapy can have a meaningful effect on cystic fibrosis and change lung function. However, they warn there is still some work to do before the treatment is ready for clinical use. About Avodart (Dutasteride) with free prescription The effectiveness needs to be improved and the correct dosing needs to be established. Lead author Eric Alton, a professor of gene therapy and respiratory medicine at Imperial College London, and consultant physician at Royal Brompton Hospital, is the coordinator of the Consortium. Stromectol (Ivermectin) with no Rx He adds that the findings also showed there were no safety concerns about the therapy, and: "Whilst the effect was inconsistent, with some patients responding better than others, the results are encouraging, laying the groundwork for further trials, which we hope could improve the effect." "We are looking to undertake follow-up studies assessing higher, more frequent doses as well as combinations with other treatments," he adds. Step change in treatment of cystic fibrosis Prof. About Centrum without prescription Alton explains that by focusing on the basic defect underlying the disease rather than just its symptoms, they aim to bring about a "step change" in the treatment of cystic fibrosis: "It has taken more than 20 years to get where we are now, and there is still some way to go. About Erectalis (Tadalafil) Eventually we hope gene therapy will push CF patients towards a normal life expectancy and improve their quality of life significantly." Funding for the trial came from a partnership between the Medical Research Council (MRC) and the National Institute for Health Research (NIHR). The Consortium is also developing a second therapy that uses a virus to deliver the corrective DNA to the lung cells. Buy Kelp online First clinical trials are expected to start in 2016. Publication of the trial results follows other welcoming news that Medical News Today reported recently of a new drug combination that targets the most common genetic cause of the disease could extend the life of cystic fibrosis patients. The trial results showed that treatment with a combination of lumacaftor and ivacaftor led to a reduction in required hospital antibiotic courses, and other improvements. Written by Catharine Paddock PhD

Navidea Biopharmaceuticals and Macrophage Therapeutics to Host Post-International KSHV Conference Summary Webcast

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. About Tricor (Fenofibrate) without Rx (NYSE MKT: NAVB) and its subsidiary, Macrophage Therapeutics, Inc., will hold a post-International Workshop on Kaposi s Sarcoma Herpesvirus (KSHV) and Related Agents conference webcast to provide investors with a more detailed look at the recently presented Manocept™ platform clinical and pre-clinical data and results disclosed in today’s press releases. Buy Colcrys (Colchicine) The webcast will take place on July 7, 2015 at 1:00 pm EDT. Orlistat (Orlistat) without prescription Rick Gonzalez, Navidea’s CEO and Michael Goldberg, M.D., Macrophage Therapeutics’ CEO will host the call along with Michael S. Captopril McGrath, M.D., Ph.D., Professor, Departments of Laboratory Medicine, Pathology, and Medicine at the University of California, San Francisco who will discuss the data presented. The webcast can be accessed at the following URL: public.viavid.com/index.php?id=115204. About Herbolax () without Rx An archived version of the webcast will be available two hours following the presentation and can be accessed within the Investors section of the Navidea website at .navidea.com. About Navidea Navidea Biopharmaceuticals, Inc. Buy Hair Loss Shampoo online (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. http://asthmareview.wordpress.com Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapeutics, and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit .navidea.com. About Macrophage Therapeutics Macrophage Therapeutics, Inc., a newly created subsidiary of Navidea Biopharmaceuticals, Inc. (NAVB), is developing therapeutics using the patented Manocept immunotherapy platform licensed from Navidea to target over-active macrophages implicated in cancer, cardiovascular, central nervous system, autoimmune, antiviral, and skin diseases. Manocept specifically targets CD206, or the mannose receptor prevalent on over-active macrophages. The technology enables highly specific targeted delivery of active (either existing or yet to be developed) agents that can modulate the activity of over-active macrophages that have been implicated in many diseases. Targeted delivery should significantly enhance a given compound’s efficacy and safety.

'Artificial pancreas' holds promise for easier control of type 1 diabetes

. Buy Hair Loss Shampoo online Orlistat (Orlistat) without prescription esearchers have created an implantable "artificial pancreas" that they say could eliminate the use of insulin injections and pumps for people with type 1 diabetes. People with type 1 diabetes have to endure multiple insulin injections daily or use an insulin pump to control their condition, but researchers say the artificial pancreas could offer a simpler management method. Francis J. http://asthmareview.wordpress.com Captopril About Tricor (Fenofibrate) without Rx Doyle and colleagues from the University of California-Santa Barbara reveal how the device can continuously measure an individual s blood glucose levels and automatically deliver insulin when required. They publish the details of their creation in the journal Industrial & Engineering Chemistry Research. According to the American Diabetes Association, around 1.25 million adults and children in the US have type 1 diabetes, of whom around 200,000 are under the age of 20. Type 1 diabetes is an autoimmune disease in which the pancreas stops producing the hormone insulin, which can result in dangerously high or low blood glucose levels. People with type 1 diabetes must measure their blood glucose levels by pricking their fingers for blood regularly throughout the day, using the measurements to calculate the insulin dose needed. To deliver insulin to the body, individuals must either inject themselves with the hormone multiple times throughout the day, or have a continuous infusion of the hormone via an insulin pump. But Doyle and colleagues say their new device could make managing type 1 diabetes much easier, abolishing the need for finger pricking and multiple injections. Optimum glucose levels maintained 78% of the time in computer tests In their study, the researchers detail the creation of a fully implantable artificial pancreas that uses an algorithm to monitor patients blood glucose levels and calculate the insulin dose needed, which is then automatically delivered to the body. On conducting computer testing of the device - involving simulation of a rise and fall in glucose levels that occurs after meals throughout the day - the team found it maintained the optimum blood glucose range of 80-140 mg/dL 78% of the time, "with no time spent in hypoglycemia." Speaking about the device at a press conference when it was first unveiled back in January, Doyle says he believes it has the potential to transform type 1 diabetes management, adding: "The closed-circuit system provides much tighter control at an unprecedented level to minimize complications and to improve the quality of life. It will have immediate benefits, as it will lower health care costs in the country and it will reduce the amount of decisions people with diabetes need to make on a constant basis." The researchers say they hope the artificial pancreas will be available for type 1 diabetes patients in the next 5 years, though the next step for the team is to conduct animal testing to "evaluate the in vivo performance" of the device. This is not the first artificial pancreas to be developed for type 1 diabetes. About Herbolax () without Rx Buy Colcrys (Colchicine) In November 2014, Medical News Today reported how a team of Canadian researchers showed how two versions of an external artificial pancreas were more effective than an insulin pump for managing the condition. Written by Honor Whiteman

'Artificial pancreas' holds promise for easier control of type 1 diabetes

. Buy Hair Loss Shampoo online Orlistat (Orlistat) without prescription esearchers have created an implantable "artificial pancreas" that they say could eliminate the use of insulin injections and pumps for people with type 1 diabetes. People with type 1 diabetes have to endure multiple insulin injections daily or use an insulin pump to control their condition, but researchers say the artificial pancreas could offer a simpler management method. Francis J. http://asthmareview.wordpress.com Captopril About Tricor (Fenofibrate) without Rx Doyle and colleagues from the University of California-Santa Barbara reveal how the device can continuously measure an individual s blood glucose levels and automatically deliver insulin when required. They publish the details of their creation in the journal Industrial & Engineering Chemistry Research. According to the American Diabetes Association, around 1.25 million adults and children in the US have type 1 diabetes, of whom around 200,000 are under the age of 20. Type 1 diabetes is an autoimmune disease in which the pancreas stops producing the hormone insulin, which can result in dangerously high or low blood glucose levels. People with type 1 diabetes must measure their blood glucose levels by pricking their fingers for blood regularly throughout the day, using the measurements to calculate the insulin dose needed. To deliver insulin to the body, individuals must either inject themselves with the hormone multiple times throughout the day, or have a continuous infusion of the hormone via an insulin pump. But Doyle and colleagues say their new device could make managing type 1 diabetes much easier, abolishing the need for finger pricking and multiple injections. Optimum glucose levels maintained 78% of the time in computer tests In their study, the researchers detail the creation of a fully implantable artificial pancreas that uses an algorithm to monitor patients blood glucose levels and calculate the insulin dose needed, which is then automatically delivered to the body. On conducting computer testing of the device - involving simulation of a rise and fall in glucose levels that occurs after meals throughout the day - the team found it maintained the optimum blood glucose range of 80-140 mg/dL 78% of the time, "with no time spent in hypoglycemia." Speaking about the device at a press conference when it was first unveiled back in January, Doyle says he believes it has the potential to transform type 1 diabetes management, adding: "The closed-circuit system provides much tighter control at an unprecedented level to minimize complications and to improve the quality of life. It will have immediate benefits, as it will lower health care costs in the country and it will reduce the amount of decisions people with diabetes need to make on a constant basis." The researchers say they hope the artificial pancreas will be available for type 1 diabetes patients in the next 5 years, though the next step for the team is to conduct animal testing to "evaluate the in vivo performance" of the device. This is not the first artificial pancreas to be developed for type 1 diabetes. About Herbolax () without Rx Buy Colcrys (Colchicine) In November 2014, Medical News Today reported how a team of Canadian researchers showed how two versions of an external artificial pancreas were more effective than an insulin pump for managing the condition. Written by Honor Whiteman